More Unbelievable Success for this Mega Blockbuster in Waiting

Generally when a drug trial is stopped early it is bad news, lack of effectiveness or a serious safety issue. Once in a rare while, a drug is working so well, that it is unfair to keep it from the placebo group and the trial is halted and unblinded. This is what happened to Bristol-Myers Squibb (NYSE: BMY) phase 3 trial for its PD1 immuno-oncology drug nivolumab. Bristol may have given up first mover advantage to fellow big pharma Merck (NYSE: MRK), but it is still a force to be reckoned with in the burgeoning field.

In this episode of Where The Money Is, Motley Fool health care analysts David Williamson and Michael Douglass discuss the trial stoppage and results, give investors background on immuno-oncology, why this drug is so important to Bristol. Watch and find out about why this tent-pole franchise has megablockbuster written all over it.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

 


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3012158, ~/Articles/ArticleHandler.aspx, 8/23/2014 2:48:12 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement